Russell Barton
Operationeel Directeur bij ACUMEN PHARMACEUTICALS, INC.
Vermogen: 284 789 $ op 31-05-2024
Actieve functies van Russell Barton
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Operationeel Directeur | 01-04-2019 | - |
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Hoofd Techniek/Wetenschap/O&O | 01-10-2019 | - |
| Pharma Sagacity Consulting LLC | President | 01-01-2018 | - |
Loopbaan van Russell Barton
Eerdere bekende functies van Russell Barton
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ELI LILLY AND COMPANY | Operationeel Directeur | - | - |
Opleiding van Russell Barton
| Illinois State University | Undergraduate Degree |
| Purdue University | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Operating Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
| Pharma Sagacity Consulting LLC |
- Beurs
- Insiders
- Russell Barton
- Ervaring
